Organon & Co. (OGN) Stock Price, News & Analysis

Company Overview

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Key Stats

• Today's Range: $14.68 to $15.36
• 50-Day Range: $14.30 to $16.41
• 52-Week Range: $13.87 to $23.10
• Volume: 3.42 million shs
• Average Volume: 2.42 million shs
• Market Capitalization: $3.80 billion
• P/E Ratio: 4.43
• Dividend Yield: 7.60%
• Price Target: $20.80
• Consensus Rating: Hold

Organon & Co. Stock Analysis - MarketRank™

Organon & Co. scored higher than 97% of companies evaluated by MarketBeat, and ranked 24th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Organon & Co. has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Organon & Co. has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 1.63%

Earnings Growth

Earnings for Organon & Co. are expected to grow by 1.63% in the coming year, from $3.68 to $3.74 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organon & Co. is 4.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organon & Co. is 4.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.58.

Price to Earnings Growth Ratio

Organon & Co. has a PEG Ratio of 0.90. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.93% of the float of Organon & Co. has been sold short.

Short Interest Ratio / Days to Cover

Organon & Co. has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Organon & Co. has recently decreased by 3.31%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Leadership

Organon & Co. is a leading dividend payer. It pays a dividend yield of 7.28%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Organon & Co. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Organon & Co. is 33.63%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Organon & Co. will have a dividend payout ratio of 29.95% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -2.37

Percentage of Shares Shorted

6.93% of the float of Organon & Co. has been sold short.

Short Interest Ratio / Days to Cover

Organon & Co. has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Organon & Co. has recently decreased by 3.31%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.40

News Sentiment

Organon & Co. has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Organon & Co. this week, compared to 5 articles on an average week.

Search Interest

Only 30 people have searched for OGN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organon & Co. insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.40% of the stock of Organon & Co. is held by insiders.

Percentage Held by Institutions

77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OGN Stock Analysis - Frequently Asked Questions

How have OGN shares performed this year?

Organon & Co.'s stock was trading at $14.92 at the beginning of the year. Since then, OGN stock has decreased by 1.2% and is now trading at $14.74.
View the best growth stocks for 2025 here.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) issued its earnings results on Thursday, February, 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by $0.09. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a trailing twelve-month return on equity of 431.62%.
Read the conference call transcript.

Who are Organon & Co.'s major shareholders?

Organon & Co.'s top institutional shareholders include Vanguard Group Inc. (11.80%), Pacer Advisors Inc. (4.33%), Massachusetts Financial Services Co. MA (3.84%) and LSV Asset Management (2.92%).
View institutional ownership trends.

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Organon & Co. own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Chevron (CVX), Bristol-Myers Squibb (BMY), McKesson (MCK), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

• Last Earnings: 2/13/2025
• Ex-Dividend for 3/13 Dividend: 2/24/2025
• Dividend Payable: 3/13/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:OGN
• CIK: 1821825
• Web: www.organon.com
• Phone: 551-430-6900
• Fax: N/A
• Employees: 10,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.80
• High Stock Price Target: $24.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +41.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $3.33
• Trailing P/E Ratio: 4.43
• Forward P/E Ratio: 4.01
• P/E Growth: 0.9
• Net Income: $864 million
• Net Margins: 13.49%
• Pretax Margin: 12.60%
• Return on Equity: 431.62%
• Return on Assets: 8.03%

Debt

• Debt-to-Equity Ratio: 17.73
• Current Ratio: 1.70
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $6.40 billion
• Price / Sales: 0.59
• Cash Flow: $4.72 per share
• Price / Cash Flow: 3.12
• Book Value: ($0.27) per share
• Price / Book: -54.59

Miscellaneous

• Outstanding Shares: 257,950,000
• Free Float: 253,933,000
• Market Cap: $3.80 billion
• Optionable: Not Optionable
• Beta: 0.76